Teva Pharmaceutical Industries Limited (TLV:TEVA)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
5,730.00
+31.00 (0.54%)
Mar 27, 2025, 5:24 PM IDT
11.35%
Market Cap 63.85B
Revenue (ttm) 60.26B
Net Income (ttm) -5.97B
Shares Out n/a
EPS (ttm) -5.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,871,448
Average Volume 1,192,355
Open 5,772.00
Previous Close 5,699.00
Day's Range 5,715.00 - 5,808.00
52-Week Range 4,807.00 - 8,431.00
Beta 0.83
RSI 42.33
Earnings Date May 7, 2025

About TLV:TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]

Sector Healthcare
Founded 1901
Employees 35,686
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol TEVA
Full Company Profile

Financial Performance

In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.

Financial numbers in USD Financial Statements

News

Teva Releases Q1 2025 Aide Memoire

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the "Investors" page on its...

1 day ago - Benzinga

Teva Releases Q1 2025 Aide Memoire

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the “Investors” page on its...

1 day ago - GlobeNewsWire

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2025 financial re...

1 day ago - GlobeNewsWire

Teva Pharmaceutical Indus Unusual Options Activity

Financial giants have made a conspicuous bearish move on Teva Pharmaceutical Indus. Our analysis of options history for Teva Pharmaceutical Indus (NYSE: TEVA) revealed 8 unusual trades. Delving into ...

1 day ago - Benzinga

Teva Pharmaceutical Industries Ltd at Barclays Global Healthcare Conference Transcript

Teva Pharmaceutical Industries Ltd at Barclays Global Healthcare Conference Transcript

8 days ago - GuruFocus

Teva Pharmaceutical Industries Ltd to Discuss New Data Presented for Duvakitug (Anti-TL1A) ...

Teva Pharmaceutical Industries Ltd to Discuss New Data Presented for Duvakitug (Anti-TL1A) Phase 2b after ECCO Conference Call Transcript

8 days ago - GuruFocus

Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript

Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript

8 days ago - GuruFocus

Teva Pharmaceutical Stock Scores RS Rating Upgrade

Teva Pharmaceutical ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

10 days ago - Investor's Business Daily

Drugmakers agree to participate in second round of price negotiations

All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals , whose medicines are part of the second round of price talks have agreed to participate in the negotiation process, a federal h...

14 days ago - Reuters

Teva Pharmaceutical Industries Limited (TEVA) Leerink's 2025 Global Healthcare Conference (Transcript)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Leerink's 2025 Global Healthcare Conference March 12, 2025 8:40 AM ETCompany ParticipantsRichard Francis...

16 days ago - Seeking Alpha

This Is What Whales Are Betting On Teva Pharmaceutical Indus

Financial giants have made a conspicuous bullish move on Teva Pharmaceutical Indus. Our analysis of options history for Teva Pharmaceutical Indus (NYSE: TEVA) revealed 8 unusual trades. Delving into ...

21 days ago - Benzinga

Deckers Outdoor Corp (DECK) Unveils Teva's Spring-Summer 2025 Collection

Deckers Outdoor Corp (DECK) Unveils Teva's Spring-Summer 2025 Collection

25 days ago - GuruFocus

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcom...

25 days ago - GlobeNewsWire

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states The $2 million in new funding is part...

4 weeks ago - GlobeNewsWire

Teva Pharmaceutical's UZEDY sNDA Accepted by FDA for Bipolar I Disorder Treatment

Teva Pharmaceutical's UZEDY sNDA Accepted by FDA for Bipolar I Disorder Treatment

4 weeks ago - GuruFocus

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (E...

4 weeks ago - GlobeNewsWire

Teva Pharmaceutical Industries Ltd (TEVA) Announces Promising Phase 2b Study Results for ...

Teva Pharmaceutical Industries Ltd (TEVA) Announces Promising Phase 2b Study Results for Duvakitug in Treating IBD

4 weeks ago - GuruFocus

Teva Pharmaceutical Industries Ltd (TEVA) Launches SELARSDI™ in the U.S.

Teva Pharmaceutical Industries Ltd (TEVA) Launches SELARSDI™ in the U.S.

4 weeks ago - GuruFocus

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn's Disease

New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on cli...

5 weeks ago - GlobeNewsWire

Final Trade: TEVA, JNJ, TJX, BABA

The final trades of the day with the Fast Money traders.

5 weeks ago - CNBC Television